Renier J. Brentjens

Medical Oncologist & Director, Cellular Therapeutics at Memorial Sloan-Kettering Cancer Center

Renier J. Brentjens

Renier J. Brentjens

Medical Oncologist & Director, Cellular Therapeutics at Memorial Sloan-Kettering Cancer Center

Overview
Career Highlights

Juno Therapeutics, Inc.

RelSci Relationships

3459

Number of Boards

1

Contact Data
Trying to get in touch with Renier J. Brentjens? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals Renier J. Brentjens likely has professional access to. A relationship does not necessarily indicate a personal connection.

Director, Center for Cell Engineering & Gene Transfer & Gene Expression Laboratory at Memorial Sloan-Kettering Cancer Center

Relationship likelihood: Strong

Founder at Agios Pharmaceuticals, Inc.

Relationship likelihood: Strong

Benno C. Schmidt Chair in Clinical Oncology at Memorial Sloan-Kettering Cancer Center

Relationship likelihood: Strong

Director at Tri-Institutional Therapeutics Discovery Institute, Inc.

Relationship likelihood: Strong

Chair, Department of Surgery at Memorial Sloan-Kettering Cancer Center

Relationship likelihood: Strong

Anne Burnett Windfohr Chair of Clinical Oncology at Memorial Sloan-Kettering Cancer Center

Relationship likelihood: Strong

Chief, Leukemia Service at Memorial Sloan-Kettering Cancer Center

Relationship likelihood: Strong

Senior Vice President, Office of the President, Medical Director, Evelyn H. Lauder Breast Center & Norna S. Sarofim Chair in Clinical Oncology at Memorial Sloan-Kettering Cancer Center

Relationship likelihood: Strong

Professor at The Rockefeller University

Relationship likelihood: Strong

Professor of Medicine, Joan & Sanford I. Weill Department of Medicine at Cornell University - Weill Cornell Medical College

Relationship likelihood: Strong

Paths to Renier J. Brentjens
Potential Connections via
Relationship Science
You
Renier J. Brentjens
Medical Oncologist & Director, Cellular Therapeutics at Memorial Sloan-Kettering Cancer Center
Education
PhD Microbiolgy

A high quality, respected college on par with a private school (but at the cost of a public school) is what makes SUNY Oswego a great choice for residents of upstate New York and the Northeast in general. Situated alongside a lake in the rural town of Oswego, New York, SUNY Oswego’s environment offers natural beauty and, with its numerous buildings that stretch across hundreds of acres, a spacious campus. At the graduate and undergraduate levels, SUNY Oswego boasts top-notch faculty, a number of whom are Fulbright scholars, published writers and award-winning researchers. In addition to learning from such exceptional faculty, many students also engage in research, another academic advantage of a SUNY Oswego education. Degrees at SUNY Oswego are granted through distinctive schools including the College of Liberal Arts and Sciences, the School of Business, a School of Education and a school for Fine and Performing Arts. Student life is equally impressive, offering over 100 academic, cultural, religious, community service and media-related student organizations. For freshman applicants who have been out of high school for fewer than three years, SAT or ACT scores are required. Additional requirements for all students include a high school diploma or GED as well as transcripts. Tuition is lower for in-state residents and financial aid options are available.

Career History
Scientific Co-Founder
Current

Juno Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of innovative cellular immunotherapy for the treatment of cancer. It offers platforms which includes chimeric antigen receptors and T-cell receptors. The company was founded by Hans E. Bishop, Lawrence Corey, Richard D. Klausner, Stan Riddell, and Robert T. Nelsen on August 5, 2013 and is headquartered in Seattle, WA.

Associate Professor of Medicine
Current

Founded in 1898, and affiliated with what is now NewYork-Presbyterian Hospital since 1927, Weill Cornell Medical College is among the top-ranked clinical and medical research centers in the country. In addition to offering degrees in medicine, Weill Cornell also has PhD programs in biomedical research and education at the Weill Cornell Graduate School of Medical Sciences, and with neighboring Sloan-Kettering Institute and The Rockefeller University, has established a joint MD-PhD program for students to intensify their pursuit of Weill Cornell's triple mission of education, research, and patient care. Weill Cornell Medical College is divided into 24 basic science and patient care departments that focus on the sciences underlying clinical medicine and/or encompass the study, treatment, and prevention of human diseases. In addition to its affiliation with NewYork-Presbyterian Hospital, Weill Cornell Medical College and the Weill Cornell Graduate School of Medical Sciences maintain major affiliations with Memorial Sloan-Kettering Cancer Center, The Rockefeller University, the Hospital for Special Surgery, as well as with the metropolitan-area institutions that constitute NewYork-Presbyterian Healthcare Network. Weill Cornell Medical College and the Weill Cornell Graduate School of Medical Sciences are accredited by the Liaison Committee for Medical Education of the American Medical Association and the Association of American Medical Colleges.

Medical Oncologist & Director, Cellular Therapeutics
Current

Memorial Sloan-Kettering Cancer Center — the world's oldest and largest private cancer center — has devoted more than 125 years to exceptional patient care, innovative research, and outstanding educational programs. Today, we are one of 41 National Cancer Institute–designated Comprehensive Cancer Centers, with state-of-the-art science flourishing side by side with clinical studies and treatment. The close collaboration between our physicians and scientists is one of our unique strengths, enabling us to provide patients with the best care available as we work to discover more-effective strategies to prevent, control, and ultimately cure cancer in the future. Our education programs train future physicians and scientists, and the knowledge and experience they gain at Memorial Sloan-Kettering has an impact on cancer treatment and biomedical research around the world.

Boards & Committees
Member, Antibody Scientific Advisory Board
Current

The mission of the Tri-Institutional Therapeutics Discovery Institute is to encourage our Tri-Institutional (Tri-I) community, made up of Memorial Sloan Kettering Cancer Center, The Rockefeller University and Weill Cornell Medicine, to advance their groundbreaking biological discoveries to preclinical studies. TDI provides industrial-scale technical support for academic projects, making it possible to rapidly assess the utility of specific therapeutic targets in disease-relevant contexts. TDI empowers the Tri-I community to translate research discoveries from bench to bedside by offering a menu of services that are unprecedented in scale and scope in an academic environment. This is accomplished through a series of highly favorable academic-industry partnerships established through TDI, as well as our Innovation & Education Initiative, which provides community-wide training and support in order to maximize the impact of these partnerships on academic drug discoveries.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Renier J. Brentjens. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Renier J. Brentjens's profile does not indicate a business or promotional relationship of any kind between RelSci and Renier J. Brentjens.